Advanced cisplatin nanoformulations as targeted drug delivery platforms for lung carcinoma treatment: a review
Source abstract
Abstract
Lung cancer accounts for the second-highest death rate globally among cancer-associated mortality. Cisplatin is a first-line chemotherapy medication used for the treatment of lung cancer. The most challenging problems in treating lung cancer with this drug include the development of drug resistance by the cells, low water solubility, and adverse effects on the normal cells. To address these concerns, nanotechnology-based drug delivery approach has shown promising results, resulting in an increase in the cellular absorption of drugs by the cancer cells with minimal adverse effects. According to the findings, cisplatin formulations including polymeric nanoparticles, micelles, dendrimers, and liposomes have a greater chance of delivering persistent cisplatin to the tumor in response to changes in the tumor microenvironment. This review deals with the various in vitro and in vivo studies of cisplatin nanoformulations and also covers the clinical trials carried out using nanocarrier-based cisplatin delivery. According to the best of our knowledge, this is the first detailed review article containing collective studies of cisplatin nanoformulations for lung cancer treatment. Schematic representation indicating the efficacy of different cisplatin-loaded nanocarriers for targeted drug delivery in lung carcinoma.
Source: expertdata · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Dendrimers and Hyperbranched Polymers · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.2166010.3322/caac.21660 ↗
2. https://www.cancer.net/about-us/cancernet-editorial-board
3. Stein JJ (1996) An evaluation of treatment methods for lung carcinoma. Am J Roentgenol 96:119–129. https://doi.org/10.2214/ajr.96.1.11910.2214/ajr.96.1.119 ↗
4. Anagnostou VK, Brahmer JR (2015) Cancer immunotherapy: a future paradigm shift in the treatment of non–small cell lung cancer. Clin Cancer Res 21:976–984. https://doi.org/10.1158/1078-043210.1158/1078-0432 ↗
5. Cox G, Jones JL, Walker RA, Steward WP, O’Byrne KJ (2000) Angiogenesis and non-small cell lung cancer. Lung Cancer 27:81–100. https://doi.org/10.1016/S0169-5002(99)00096-310.1016/S0169-5002(99)00096-3 ↗
6. Cryer AM, Thorley AJ (2019) Nanotechnology in the diagnosis and treatment of lung cancer. Pharmacol Ther 198:189–205. https://doi.org/10.1016/j.pharmthera.2019.02.01010.1016/j.pharmthera.2019.02.010 ↗
7. Shiono S, Katahira M, Abiko M, Sato T (2015) Smoking is a perioperative risk factor and prognostic factor for lung cancer surgery. J Thorac Cardiovasc Surg 63:93–98. https://doi.org/10.1007/s11748-014-0461-310.1007/s11748-014-0461-3 ↗
8. Ihde DC (1992) Chemotherapy of lung cancer. N Engl J Med 327:1434–1441. https://doi.org/10.1056/NEJM19921112327200610.1056/NEJM199211123272006 ↗
9. Hanania AN, Mainwaring W, Ghebre YT, Hanania NA, Ludwig M (2019) Radiation-induced lung injury: assessment and management. Chest 156:150–162. https://doi.org/10.1016/j.chest.2019.03.03310.1016/j.chest.2019.03.033 ↗
10. Ming X, Feng Y, Yang C, Wang W, Wang P, Deng J (2016) Radiation-induced heart disease in lung cancer radiotherapy: a dosimetric update. Medicine 95:41–46. https://doi.org/10.1097/MD.000000000000505110.1097/MD.0000000000005051 ↗
11. Assoun S, Brosseau S, Steinmetz C, Gounant V, Zalcman G (2017) Bevacizumab in advanced lung cancer: state of the art. Future Oncol 13:2515–2535. https://doi.org/10.2217/fon-2017-030210.2217/fon-2017-0302 ↗
12. Shih T, Lindley C (2006) Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28:1779–1802. https://doi.org/10.1016/j.clinthera.2006.11.01510.1016/j.clinthera.2006.11.015 ↗
13. Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307–320. https://doi.org/10.1038/nrd169110.1038/nrd1691 ↗
14. Jamieson ER, Lippard SJ (1999) Structure, recognition, and processing of cisplatin—DNA adducts. Chem Rev 99:2467–2498. https://doi.org/10.1021/cr980421n10.1021/cr980421n ↗
15. Gispen WH, Hamers FP, Neijt JP (1990) Neurotoxic side-effects of cisplatin. Eur J Cancer 27:372–376
16. Duan Z, Cai G, Li J, Chen X (2020) Cisplatin-induced renal toxicity in elderly people. Ther Adv Med Oncol 12:1–15. https://doi.org/10.1177/175883592092343010.1177/1758835920923430 ↗
17. Shahid F, Farooqui Z, Khan F (2018) Cisplatin-induced gastrointestinal toxicity: an update on possible mechanisms and on available gastroprotective strategies. Eur J Pharmacol 827:49–57. https://doi.org/10.1016/j.ejphar.2018.03.00910.1016/j.ejphar.2018.03.009 ↗
18. Yue Z, Cao Z (2016) Current strategy for cisplatin delivery. Curr Cancer Drug Targets 16:480–48810.2174/1568009616666160328113006 ↗
19. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, Cucevic B (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. The Lancet 374:1432–1440. https://doi.org/10.1016/S0140-6736(09)61497-510.1016/S0140-6736(09)61497-5 ↗
20. Farrell D, Ptak K, Panaro NJ, Grodzinski P (2011) Nanotechnology-based cancer therapeutics—promise and challenge—lessons learned through the NCI alliance for nanotechnology in cancer. Pharm Res 28:273–278. https://doi.org/10.1007/s11095-010-0214-710.1007/s11095-010-0214-7 ↗
21. Sutradhar KB, Amin M (2014) Nanotechnology in cancer drug delivery and selective targeting. Int Sch Res Notices 2014:1–12. https://doi.org/10.1155/2014/93937810.1155/2014/939378 ↗
22. Kesharwani P (2019) Nanotechnology-based targeted drug delivery systems for lung cancer. Academic Press
23. Prasad R, Pandey R, Varma R, Barman I (2016) Polymer based nanoparticles for drug delivery systems and cancer therapeutics. Oxfordshire, pp 53–7010.1079/9781780644479.0053 ↗
24. Agarwal A, Asthana A, Gupta U, Jain NK (2008) Tumor and dendrimers: a review on drug delivery aspects. J Pharm Pharmacol 60:671–688. https://doi.org/10.1211/jpp.60.6.000110.1211/jpp.60.6.0001 ↗
25. Maya S, Sarmento B, Nair A, Rejinold NS, Nair SV, Jayakumar R (2013) Smart stimuli sensitive nanogels in cancer drug delivery and imaging: a review. Curr Pharm Des 19:7203–7218. https://doi.org/10.2174/13816128194113121912414210.2174/138161281941131219124142 ↗
26. Pillai G (2019) Nanotechnology toward treating cancer: a comprehensive review. Appl Targeted Nano Drugs Deliv Syst 2019:221–256. https://doi.org/10.1016/B978-0-12-814029-1.00009-010.1016/B978-0-12-814029-1.00009-0 ↗
27. Aldossary SA (2019) Review on pharmacology of cisplatin: clinical use, toxicity and mechanism of resistance of cisplatin. Pharmacol J 12:15–16. https://doi.org/10.13005/bpj/160810.13005/bpj/1608 ↗
28. Na JH, Lee S, Koo H, Han H, Lee KE, Han SJ, Choi SH, Kim H, Lee S, Kwon IC, Choi K (2016) T1-weighted mr imaging of liver tumor by gadolinium-encapsulated glycol chitosan nanoparticles without non-specific toxicity in normal tissues. Nanoscale 8:9736–9745. https://doi.org/10.1039/C5NR06673E10.1039/C5NR06673E ↗
29. Ghaferi M, Amari S, Vivek Mohrir B, Raza A, Ebrahimi Shahmabadi H, Alavi SE (2020) Preparation, characterization, and evaluation of cisplatin-loaded polybutylcyanoacrylate nanoparticles with improved in vitro and in vivo anticancer activities. Pharmaceuticals 13:44. https://doi.org/10.3390/ph1303004410.3390/ph13030044 ↗
30. Wu H, Jin H, Wang C, Zhang Z, Ruan H, Sun L, Yang C, Li Y, Qin W, Wang C (2017) Synergistic cisplatin/doxorubicin combination chemotherapy for multidrug-resistant cancer via polymeric nanogels targeting delivery. ACS Appl Mater 9:9426–9436. https://doi.org/10.1021/acsami.6b1684410.1021/acsami.6b16844 ↗
31. Koganti S, Jagani HV, Palanimuthu VR, Mathew JA, Rao MC, Rao JV (2013) In vitro and in vivo evaluation of the efficacy of nanoformulation of siRNA as an adjuvant to improve the anticancer potential of cisplatin. Exp Mol Pathol 94:137–147. https://doi.org/10.1016/j.yexmp.2012.10.00710.1016/j.yexmp.2012.10.007 ↗
32. Neamtu I, Rusu AG, Diaconu A, Nita LE, Chiriac AP (2017) Basic concepts and recent advances in nanogels as carriers for medical applications. Drug Deliv 24:539–557. https://doi.org/10.1080/10717544.2016.127623210.1080/10717544.2016.1276232 ↗
33. Gil MS, Thambi T, Phan VG, Kim SH, Lee DS (2017) Injectable hydrogel-incorporated cancer cell-specific cisplatin releasing nanogels for targeted drug delivery. J Mater Chem B 5:7140–7152. https://doi.org/10.1039/C7TB00873B10.1039/C7TB00873B ↗
34. Sun M, He L, Fan Z, Tang R, Du J (2020) Effective treatment of drug-resistant lung cancer via a nanogel capable of reactivating cisplatin and enhancing early apoptosis. Biomaterials 257:120252. https://doi.org/10.1016/j.biomaterials.2020.12025210.1016/j.biomaterials.2020.120252 ↗
35. Gonzalez-Urias A, Zapata-Gonzalez I, Licea-Claverie A, Licea-Navarro AF, Bernaldez-Sarabia J, Cervantes-Luevano K (2019) Cationic versus anionic core-shell nanogels for transport of cisplatin to lung cancer cells. Colloids Surf B Biointerfaces 182:110365. https://doi.org/10.1016/j.colsurfb.2019.11036510.1016/j.colsurfb.2019.110365 ↗
36. Zhang W, Tung CH (2018) Redox-responsive cisplatin nanogels for anticancer drug delivery. Chem Commun 54:8367–8370. https://doi.org/10.1039/C8CC01795F10.1039/C8CC01795F ↗
37. González-Urías A, Manzanares-Guevara LA, Licea-Claveríe Á, Ochoa-Terán A, Licea-Navarro AF, Bernaldez-Sarabia J, Zapata-González I (2021) Stimuli responsive nanogels with intrinsic fluorescence: Promising nanovehicles for controlled drug delivery and cell internalization detection in diverse cancer cell lines. Eur Polym J 144:110200. https://doi.org/10.1016/j.eurpolymj.2020.11020010.1016/j.eurpolymj.2020.110200 ↗
38. Daraee H, Etemadi A, Kouhi M, Alimirzalu S, Akbarzadeh A (2016) Application of liposomes in medicine and drug delivery. Nanomed Biotech 44:381–391. https://doi.org/10.3109/21691401.2014.95363310.3109/21691401.2014.953633 ↗
39. Carvalho Júnior AD, Vieira FP, De Melo VJ, Lopes MT, Silveira JN, Ramaldes GA, Garnier-Suillerot A, Pereira-Maia EC, De Oliveira MC (2007) Preparation and cytotoxicity of cisplatin-containing liposomes. Braz J Med Biol Res 40:1149–1157. https://doi.org/10.1590/S0100-879X200600500012510.1590/S0100-879X2006005000125 ↗
40. Xiao CJ, Qi XR, Aini W, Wei SL (2003) Preparation of cisplatin multivesicular liposomes and release of cisplatin from the liposomes in vitro. Yao xuexue bao Acta Pharm Sin 38:133–137
41. Vhora I, Khatri N, Desai J, Thakkar HP (2014) Caprylate-conjugated cisplatin for the development of novel liposomal formulation. AAPS Pharm Sci Tech 15:845–857. https://doi.org/10.1208/s12249-014-0106-y10.1208/s12249-014-0106-y ↗
42. Araújo RS, Silveira AL, e Souza ÉL, Freire RH, de Souza CM, Reis DC, Costa BR, Sugimoto MA, Silveira JN, dos Santos Martins F, Cassali GD (2017) Intestinal toxicity evaluation of long-circulating and pH-sensitive liposomes loaded with cisplatin. Eur J Pharm Sci 106: 142–51. https://doi.org/10.1016/j.ejps.2017.05.04610.1016/j.ejps.2017.05.046 ↗
43. Sun XY, Liang WQ (2011) Comparison on antitumor activity of cisplatin-loaded liposomes and nanoparticles in vitro. J Zhejiang Univ Med Sci 40:408–413
44. Wu M, Huang T, Wang J, Chen P, Mi W, Ying Y, Wang H, Zhao D, Huang S (2018) Antilung cancer effect of ergosterol and cisplatin-loaded liposomes modified with cyclic arginine-glycine-aspartic acid and octa-arginine peptides. Medicine 97:33. https://doi.org/10.1097/MD.000000000001191610.1097/MD.0000000000011916 ↗
45. Song J, Ren W, Xu T, Zhang Y, Guo H, Zhu S, Yang L (2017) Reversal of multidrug resistance in human lung cancer cells by delivery of 3-octadecylcarbamoylacrylic acid–cisplatin-based liposomes. Drug Des Dev Ther 11:441. https://doi.org/10.2147/DDDT.S12491210.2147/DDDT.S124912 ↗
46. Wang S, Gou J, Wang Y, Tan X, Zhao L, Jin X, Tang X (2021) Synergistic antitumor efficacy mediated by liposomal co-delivery of polymeric micelles of vinorelbine and cisplatin in non-small cell lung cancer. Int J Nanomed 16:2357. https://doi.org/10.2147/IJN.S29026310.2147/IJN.S290263 ↗
47. Dou YN, Dunne M, Huang H, Mckee T, Chang MC, Jaffray DA, Allen C (2016) Thermosensitive liposomal cisplatin in combination with local hyperthermia results in tumor growth delay and changes in tumor microenvironment in xenograft models of lung carcinoma. J Drug Target 24:865–877. https://doi.org/10.1080/1061186X.2016.119107910.1080/1061186X.2016.1191079 ↗
48. Yang YT, Shi Y, Jay M, Di Pasqua AJ (2014) Enhanced toxicity of cisplatin with chemosensitizer phenethyl isothiocyanate toward non-small cell lung cancer cells when delivered in liposomal nanoparticles. Chem Res Toxicol 27:946–948. https://doi.org/10.1021/tx500112810.1021/tx5001128 ↗
49. Jin Y, Wang Y, Liu X, Zhou J, Wang X, Feng H, Liu H (2020) Synergistic combination chemotherapy of lung cancer: cisplatin and doxorubicin conjugated prodrug loaded, glutathione and pH sensitive nanocarriers. Drug Des Dev Ther 14:5205. https://doi.org/10.2147/DDDT.S26025310.2147/DDDT.S260253 ↗
50. Li C, Li T, Huang L, Yang M, Zhu G (2019) Self-assembled lipid nanoparticles for ratiometric codelivery of cisplatin and siRNA targeting XPF to combat drug resistance in lung cancer. Chem Asian J 14:1570–1576. https://doi.org/10.1002/asia.20190000510.1002/asia.201900005 ↗
51. Croy SR, Kwon GS (2006) Polymeric micelles for drug delivery. Curr Pharm Des 12:4669–4684. https://doi.org/10.2174/13816120677902624510.2174/138161206779026245 ↗
52. He L, Xu J, Cheng X, Sun M, Wei B, Xiong N, Song J, Wang X, Tang R (2020) Hybrid micelles based on Pt (IV) polymeric prodrug and TPGS for the enhanced cytotoxicity in drug-resistant lung cancer cells. Surf B Biointerfaces 195:111256. https://doi.org/10.1016/j.colsurfb.2020.11125610.1016/j.colsurfb.2020.111256 ↗
53. Wan X, Min Y, Bludau H, Keith A, Sheiko SS, Jordan R, Wang AZ, Sokolsky-Papkov M, Kabanov AV (2018) Drug combination synergy in worm-like polymeric micelles improves treatment outcome for small cell and non-small cell lung cancer. ACS Nano 12:2426–2439. https://doi.org/10.1021/acsnano.7b0787810.1021/acsnano.7b07878 ↗
54. Song W, Li M, Tang Z, Li Q, Yang Y, Liu H, Duan T, Hong H, Chen X (2012) Methoxypoly (ethylene glycol)-block-Poly (L-glutamic acid)-loaded cisplatin and a combination with iRGD for the treatment of non-small-cell lung cancers. Macromol Biosci 12:1514–1523. https://doi.org/10.1002/mabi.20120014510.1002/mabi.201200145 ↗
55. Zhu YH, Sun CY, Shen S, Khan MI, Zhao YY, Liu Y, Wang YC, Wang J (2017) A micellar cisplatin prodrug simultaneously eliminates both cancer cells and cancer stem cells in lung cancer. Biomater Sci 5:1612–1621. https://doi.org/10.1039/C7BM00278E10.1039/C7BM00278E ↗
56. Han Y, Li J, Zan M, Luo S, Ge Z, Liu S (2014) Redox-responsive core cross-linked micelles based on cypate and cisplatin prodrugs-conjugated block copolymers for synergistic photothermal–chemotherapy of cancer. Polym Chem 5:3707–3718. https://doi.org/10.1039/C4PY00064A10.1039/C4PY00064A ↗
57. Song W, Tang Z, Li M, Lv S, Sun H, Deng M, Liu H, Chen X (2014) Polypeptide-based combination of paclitaxel and cisplatin for enhanced chemotherapy efficacy and reduced side-effects. Acta Biomater 10:1392–1402. https://doi.org/10.1016/j.actbio.2013.11.02610.1016/j.actbio.2013.11.026 ↗
58. Li J, Han Y, Chen Q, Shi H, ur Rehman S, Siddiq M, Ge Z, Liu S (2014) Dual endogenous stimuli-responsive polyplex micelles as smart two-step delivery nanocarriers for deep tumor tissue penetration and combating drug resistance of cisplatin. J Mater Chem B 2:1813–1824. https://doi.org/10.1039/C3TB21383H10.1039/C3TB21383H ↗
59. Li J, Ke W, Li H, Zha Z, Han Y, Ge Z (2015) Endogenous stimuli-sensitive multistage polymeric micelleplex anticancer drug delivery system for efficient tumor penetration and cellular internalization. Adv Mater 4:2206–2219. https://doi.org/10.1002/adhm.20150037910.1002/adhm.201500379 ↗
60. Li M, Tang Z, Lv S, Song W, Hong H, Jing X, Zhang Y, Chen X (2014) Cisplatin crosslinked pH-sensitive nanoparticles for efficient delivery of doxorubicin. Biomaterials 35:3851–3864. https://doi.org/10.1016/j.biomaterials.2014.01.01810.1016/j.biomaterials.2014.01.018 ↗
61. Uchino H, Matsumura Y, Negishi T, Koizumi F, Hayashi T, Honda T, Nishiyama N, Kataoka K, Naito S, Kakizoe T (2005) Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer 93:678–687. https://doi.org/10.1038/sj.bjc.660277210.1038/sj.bjc.6602772 ↗
62. Sun Y, Yang J, Yang T, Li Y, Zhu R, Hou Y, Liu Y (2021) Co-delivery of IL-12 cytokine gene and cisplatin prodrug by a polymetformin-conjugated nanosystem for lung cancer chemo-gene treatment through chemotherapy sensitization and tumor microenvironment modulation. Acta Biomater 128:447–461. https://doi.org/10.1016/j.actbio.2021.04.03410.1016/j.actbio.2021.04.034 ↗
63. Liu M, Fréchet JM (1999) Designing dendrimers for drug delivery. Pharmaceut Sci TechToday 2:393–401. https://doi.org/10.1016/S1461-5347(99)00203-510.1016/S1461-5347(99)00203-5 ↗
64. Svenson S, Tomalia DA (2012) Dendrimers in biomedical applications—reflections on the field. Adv Drug Deliv Rev 64:102–115. https://doi.org/10.1016/j.addr.2012.09.03010.1016/j.addr.2012.09.030 ↗
65. Palmerston Mendes L, Pan J, Torchilin VP (2017) Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy. Molecules 22:1401. https://doi.org/10.3390/molecules2209140110.3390/molecules22091401 ↗
66. Amreddy N, Babu A, Panneerselvam J, Srivastava A, Muralidharan R, Chen A, Zhao YD, Munshi A, Ramesh R (2018) Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment. Nanomed Nanotechnol Biol Med 14:373–384. https://doi.org/10.1016/j.nano.2017.11.01010.1016/j.nano.2017.11.010 ↗
67. Nguyen H, Nguyen NH, Tran NQ, Nguyen CK (2015) Improved method for preparing cisplatin-dendrimer nanocomplex and its behavior against NCI-H460 lung cancer cell. J Nanosci Nanotechnol 15:4106–4110. https://doi.org/10.1166/jnn.2015.980810.1166/jnn.2015.9808 ↗
68. Kulhari H, Pooja D, Singh MK, Chauhan AS (2015) Optimization of carboxylate-terminated poly (amidoamine) dendrimer-mediated cisplatin formulation. Drug Dev Ind Pharm 41:232–238. https://doi.org/10.3109/03639045.2013.85873510.3109/03639045.2013.858735 ↗
69. Zheng W, Cao C, Liu Y, Yu Q, Zheng C, Sun D, Ren X, Liu J (2015) Multifunctional polyamidoamine-modified selenium nanoparticles dual-delivering siRNA and cisplatin to A549/DDP cells for reversal multidrug resistance. Acta Biomater 11:368–380. https://doi.org/10.1016/j.actbio.2014.08.03510.1016/j.actbio.2014.08.035 ↗
70. Li Y, Li Y, Zhang X, Xu X, Zhang Z, Hu C, He Y, Gu Z (2016) Supramolecular PEGylated dendritic systems as pH/redox dual-responsive theranostic nanoplatforms for platinum drug delivery and NIR imaging. Theranostics 6:1293. https://doi.org/10.7150/thno.1508110.7150/thno.15081 ↗
71. González-Pastor R, Lancelot A, Morcuende-Ventura V, San Anselmo M, Sierra T, Serrano JL, Martin-Duque P (2021) Combination Chemotherapy with cisplatin and chloroquine: effect of encapsulation in micelles formed by self-assembling hybrid dendritic–linear–dendritic block copolymers. Int J Mol Sci 22:5223. https://doi.org/10.3390/ijms2210522310.3390/ijms22105223 ↗
72. Elsabahy M, Wooley KL (2012) Design of polymeric nanoparticles for biomedical delivery applications. Chem Soc Rev 41:2545–2561. https://doi.org/10.1039/C2CS15327K10.1039/C2CS15327K ↗
73. Zhang M, Hagan CT IV, Foley H, Tian X, Yang F, Au KM, Mi Y, Medik Y, Roche K, Wagner K, Rodgers Z (2021) Co-delivery of etoposide and cisplatin in dual-drug loaded nanoparticles synergistically improves chemoradiotherapy in non-small cell lung cancer models. Acta Biomater 124:327–335. https://doi.org/10.1016/j.actbio.2021.02.00110.1016/j.actbio.2021.02.001 ↗
74. Li F, Li T, Cao W, Wang L, Xu H (2017) Near-infrared light stimuli-responsive synergistic therapy nanoplatforms based on the coordination of tellurium-containing block polymer and cisplatin for cancer treatment. Biomaterials 133:208–218. https://doi.org/10.1016/j.biomaterials.2017.04.03210.1016/j.biomaterials.2017.04.032 ↗
75. Mukerabigwi JF, Han Y, Lu N, Ke W, Wang Y, Zhou Q, Mohammed F, Ibrahim A, Zheng B, Ge Z (2021) Cisplatin resistance reversal in lung cancer by tumor acidity-activable vesicular nanoreactors via tumor oxidative stress amplification. J Mater Chem B 9:3055–3067. https://doi.org/10.1039/D0TB02876B10.1039/D0TB02876B ↗
76. Patel V, Lalani R, Vhora I, Bardoliwala D, Patel A, Ghosh S, Misra A (2021) Co-delivery of cisplatin and siRNA through hybrid nanocarrier platform for masking resistance to chemotherapy in lung cancer. Drug Deliv Transl Res 5:2052–2071. https://doi.org/10.1007/s13346-020-00867-510.1007/s13346-020-00867-5 ↗
77. Nejati-Koshki K, Mesgari M, Ebrahimi E, Abbasalizadeh F, Fekri Aval S, Khandaghi AA, Abasi M, Akbarzadeh A (2014) Synthesis and in vitro study of cisplatin-loaded Fe3O4 nanoparticles modified with PLGA-PEG6000 copolymers in treatment of lung cancer. J Microencapsul 31:815–823. https://doi.org/10.3109/02652048.2014.94001110.3109/02652048.2014.940011 ↗
78. Tong NA, Nguyen TP, Cuu Khoa N, Tran NQ (2016) Aquated cisplatin and heparin-pluronic nanocomplexes exhibiting sustainable release of active platinum compound and NCI-H460 lung cancer cell antiproliferation. J Biomater Sci Polym Ed 27:709–720. https://doi.org/10.1080/09205063.2016.115423910.1080/09205063.2016.1154239 ↗
79. Hong Y, Che S, Hui B, Wang X, Zhang X, Ma H (2020) Combination therapy of lung cancer using layer-by-layer cisplatin prodrug and curcumin co-encapsulated nanomedicine. Drug Des Dev Ther 14:2263. https://doi.org/10.2147/DDDT.S24129110.2147/DDDT.S241291 ↗
80. Shi C, Yu H, Sun D, Ma L, Tang Z, Xiao Q, Chen X (2015) Cisplatin-loaded polymeric nanoparticles: characterization and potential exploitation for the treatment of non-small cell lung carcinoma. Acta Biomater 18:68–76. https://doi.org/10.1016/j.actbio.2015.02.00910.1016/j.actbio.2015.02.009 ↗
81. Tseng CL, Su WY, Yen KC, Yang KC, Lin FH (2009) The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials 30:3476–3485. https://doi.org/10.1016/j.biomaterials.2009.03.01010.1016/j.biomaterials.2009.03.010 ↗
82. Zhou Z (2020) Co-drug delivery of regorafenib and cisplatin with amphiphilic copolymer nanoparticles: enhanced in vivo antitumor cancer therapy in nursing care. Drug Deliv 27:1319–1328. https://doi.org/10.1080/10717544.2020.181589710.1080/10717544.2020.1815897 ↗
83. He Z, Huang J, Xu Y, Zhang X, Teng Y, Huang C, Wu Y, Zhang X, Zhang H, Sun W (2015) Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer. Oncotarget 6:42150. https://doi.org/10.18632/oncotarget.624310.18632/oncotarget.6243 ↗
84. Wang Z, Li Y, Zhang T, Li H, Yang Z, Wang C (2021) Effect of micelle-incorporated cisplatin with sizes ranging from 8 to 40 nm for the therapy of lewis lung carcinoma. Front Pharmacol 12:632877. https://doi.org/10.3389/fphar.2021.63287710.3389/fphar.2021.632877 ↗
85. Yang T, Yu S, Liu L, Sun Y, Lan Y, Ma X, Zhu R, Li L, Hou Y, Liu Y (2020) Dual polymeric prodrug co-assembled nanoparticles with precise ratiometric co-delivery of cisplatin and metformin for lung cancer chemoimmunotherapy. Biomater Sci 8:5698–5714. https://doi.org/10.1039/D0BM01191F10.1039/D0BM01191F ↗
86. Su WP, Cheng FY, Shieh DB, Yeh CS, Su WC (2012) PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells. Int J Nanomed 7:4269. https://doi.org/10.2147/IJN.S3366610.2147/IJN.S33666 ↗
87. Xu C, Wang Y, Guo Z, Chen J, Lin L, Wu J, Tian H, Chen X (2019) Pulmonary delivery by exploiting doxorubicin and cisplatin co-loaded nanoparticles for metastatic lung cancer therapy. J Control Release 295:153–163. https://doi.org/10.1016/j.jconrel.2018.12.01310.1016/j.jconrel.2018.12.013 ↗
88. Yu H, Tang Z, Zhang D, Song W, Zhang Y, Yang Y, Ahmad Z, Chen X (2015) Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly (L-glutamic acid)-g-methoxy poly (ethylene glycol) complex nanoparticles for tumor therapy. J Control Release 205:89–97. https://doi.org/10.1016/j.jconrel.2014.12.02210.1016/j.jconrel.2014.12.022 ↗
89. Lo YL, Huang XS, Chen HY, Huang YC, Liao ZX, Wang LF (2021) ROP and ATRP fabricated redox sensitive micelles based on PCL-SS-PMAA diblock copolymers to co-deliver PTX and CDDP for lung cancer therapy. Colloids Surf B Biointerfaces 198:111443. https://doi.org/10.1016/j.colsurfb.2020.11144310.1016/j.colsurfb.2020.111443 ↗
90. Nascimento AV, Singh A, Bousbaa H, Ferreira D, Sarmento B, Amiji MM (2017) Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles. Acta Biomater 47:71–80. https://doi.org/10.1016/j.actbio.2016.09.04510.1016/j.actbio.2016.09.045 ↗
91. Motasem MA, Obaidat RM, Alnaief M, Albiss BA, Hailat N (2020) Development, in vitro characterization, and in vivo toxicity evaluation of chitosan-alginate nanoporous carriers loaded with cisplatin for lung cancer treatment. AAPS Pharm Sci Tech 21:1–2. https://doi.org/10.1208/s12249-020-01735-810.1208/s12249-020-01735-8 ↗
92. Qu J, Liu Y, Yu Y, Li J, Luo J, Li M (2014) Silk fibroin nanoparticles prepared by electrospray as controlled release carriers of cisplatin. Mater Sci Eng C 44:166–174. https://doi.org/10.1016/j.msec.2014.08.03410.1016/j.msec.2014.08.034 ↗
93. Ling X, Tu J, Wang J, Shajii A, Kong N, Feng C, Zhang Y, Yu M, Xie T, Bharwani Z, Aljaeid BM (2018) Glutathione-responsive prodrug nanoparticles for effective drug delivery and cancer therapy. ACS Nano 13:357–370. https://doi.org/10.1021/acsnano.8b0640010.1021/acsnano.8b06400 ↗
94. Xiong Y, Zhao Y, Miao L, Lin CM, Huang L (2016) Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles to treat non-small cell lung cancer. J Control Release 244:63–73. https://doi.org/10.1016/j.jconrel.2016.11.00510.1016/j.jconrel.2016.11.005 ↗
95. He Z, Shi Z, Sun W, Ma J, Xia J, Zhang X, Chen W, Huang J (2016) Hemocompatibility of folic-acid-conjugated amphiphilic PEG-PLGA copolymer nanoparticles for co-delivery of cisplatin and paclitaxel: treatment effects for non-small-cell lung cancer. Tumor Biol 37:7809–7821. https://doi.org/10.1007/s13277-015-4634-110.1007/s13277-015-4634-1 ↗
96. Wu R, Zhang Z, Wang B, Chen G, Zhang Y, Deng H, Tang Z, Mao J, Wang L (2020) Combination chemotherapy of lung cancer–co-delivery of docetaxel prodrug and cisplatin using aptamer-decorated lipid–polymer hybrid nanoparticles. Drug Des Dev Ther 14:2249. https://doi.org/10.2147/DDDT.S24657410.2147/DDDT.S246574 ↗
97. Tian J, Min Y, Rodgers Z, Au KM, Hagan CT, Zhang M, Roche K, Yang F, Wagner K, Wang AZ (2017) Co-delivery of paclitaxel and cisplatin with biocompatible PLGA–PEG nanoparticles enhances chemoradiotherapy in non-small cell lung cancer models. J Mater Chem B5:6049–6057. https://doi.org/10.1039/C7TB01370A10.1039/C7TB01370A ↗
98. Obonyo O, Fisher E, Edwards M, Douroumis D (2010) Quantum dots synthesis and biological applications as imaging and drug delivery systems. Crit Rev Biotechnol 30:283–301. https://doi.org/10.3109/07388551.2010.48718410.3109/07388551.2010.487184 ↗
99. Sui X, Luo C, Wang C, Zhang F, Zhang J, Guo S (2016) Graphene quantum dots enhance anticancer activity of cisplatin via increasing its cellular and nuclear uptake. Nanomed Nanotechnol Biol Med 12:1997–2006. https://doi.org/10.1016/j.nano.2016.03.01010.1016/j.nano.2016.03.010 ↗
100. Tan S, Wang G (2018) Lung cancer targeted therapy: folate and transferrin dual targeted, glutathione responsive nanocarriers for the delivery of cisplatin. Biomed Pharmacother 102:55–63. https://doi.org/10.1016/j.biopha.2018.03.04610.1016/j.biopha.2018.03.046 ↗